> top > docs > PubMed:31147635 > annotations

PubMed:31147635 JSONTXT

Annnotations TAB JSON ListView MergeView

sonoma

Id Subject Object Predicate Lexical cue
T0 29-56 DISEASE denotes Duchenne muscular dystrophy
T1 58-85 DISEASE denotes Duchenne muscular dystrophy
T2 87-90 DISEASE denotes DMD
T3 95-101 REG denotes caused
T4 109-113 NEGREG denotes lack
T5 128-146 GENE denotes dystrophin protein
T6 205-211 NEGREG denotes slowed
T7 212-216 NEGREG denotes down
T8 225-236 CPA denotes progression
T9 268-272 NEGREG denotes stop
T10 288-292 NEGREG denotes loss
T11 296-309 CPA denotes muscle tissue
T12 314-322 CPA denotes function
T13 330-335 REG denotes leads
T14 339-354 CPA denotes premature death
T15 411-414 DISEASE denotes DMD
T16 416-429 VAR denotes Gene-addition
T17 431-444 VAR denotes exon-skipping
T18 502-509 POSREG denotes restore
T19 514-524 MPA denotes expression
T20 549-567 GENE denotes dystrophin protein
T21 613-620 POSREG denotes improve
T22 621-636 CPA denotes muscle function
T23 652-661 REG denotes targeting
T24 662-670 PATHWAY denotes pathways
T25 671-679 REG denotes involved
T26 703-706 DISEASE denotes DMD
R0 T1 T3 ThemeOf Duchenne muscular dystrophy,caused
R1 T2 T3 ThemeOf DMD,caused
R2 T4 T3 CauseOf lack,caused
R3 T5 T4 ThemeOf dystrophin protein,lack
R4 T8 T7 ThemeOf progression,down
R5 T11 T10 ThemeOf muscle tissue,loss
R6 T12 T10 ThemeOf function,loss
R7 T14 T13 ThemeOf premature death,leads
R8 T16 T18 CauseOf Gene-addition,restore
R9 T17 T18 CauseOf exon-skipping,restore
R10 T19 T18 ThemeOf expression,restore
R11 T20 T19 ThemeOf dystrophin protein,expression
R12 T22 T21 ThemeOf muscle function,improve
R13 T23 T21 CauseOf targeting,improve
R14 T24 T23 ThemeOf pathways,targeting
R15 T24 T25 ThemeOf pathways,involved
R16 T26 T23 ThemeOf DMD,targeting
R17 T26 T25 ThemeOf DMD,involved

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-57 Sentence denotes Therapeutic developments for Duchenne muscular dystrophy.
T2 58-147 Sentence denotes Duchenne muscular dystrophy (DMD) is caused by the lack of functional dystrophin protein.
T3 148-355 Sentence denotes Improvements in patient care and disease management have slowed down disease progression, but current treatments cannot stop the relentless loss of muscle tissue and function, which leads to premature death.
T4 356-415 Sentence denotes Research is ongoing to develop effective therapies for DMD.
T5 416-707 Sentence denotes Gene-addition, exon-skipping, stop codon readthrough and genome-editing therapies can restore the expression of partially functional dystrophin protein, whereas other therapeutic approaches aim to improve muscle function and quality by targeting pathways involved in the pathogenesis of DMD.
T6 708-885 Sentence denotes This Review outlines important developments in these research areas and specifically focuses on new therapies that are in the clinical trial phase or have already been approved.
T1 0-57 Sentence denotes Therapeutic developments for Duchenne muscular dystrophy.
T2 58-147 Sentence denotes Duchenne muscular dystrophy (DMD) is caused by the lack of functional dystrophin protein.
T3 148-355 Sentence denotes Improvements in patient care and disease management have slowed down disease progression, but current treatments cannot stop the relentless loss of muscle tissue and function, which leads to premature death.
T4 356-415 Sentence denotes Research is ongoing to develop effective therapies for DMD.
T5 416-707 Sentence denotes Gene-addition, exon-skipping, stop codon readthrough and genome-editing therapies can restore the expression of partially functional dystrophin protein, whereas other therapeutic approaches aim to improve muscle function and quality by targeting pathways involved in the pathogenesis of DMD.
T6 708-885 Sentence denotes This Review outlines important developments in these research areas and specifically focuses on new therapies that are in the clinical trial phase or have already been approved.